Astrazeneca Pharma India Ltd

The provided pages of the AstraZeneca ASH 2019 presentation (310.pdf) do not explicitly mention any current or future capital expenditure (capex), capital investments, or strategic investments. The focus is mainly on: - Clinical trial updates for Calquence in CLL (ELEVATE TN, ASCEND trials). - Product pipeline progress including new agents (AZD5991, AZD4573, AZD2811, AZD0466). - Regulatory submissions planned in H1 2020. - Sales performance and patient numbers. - Safety and efficacy data from trials. - Forward-looking statements highlighting general risks but no specific capex plans. No direct references to capex, capital investment plans, or strategic investments are detailed in the provided content.

- Calquence has generated $173 million in worldwide sales since its launch in November 2017. (Page 22) - There are ongoing Phase III trials and regulatory submissions expected to expand indications and markets, including: - ACE-CL-309 ASCEND in relapsed/refractory CLL (Approved in US) - ACE-CL-007 ELEVATE TN in previously-untreated CLL (Approved in US) - Calquence regulatory submissions in EU and Japan targeted for H1 2020 - ACE-CL-006 ELEVATE RR in relapsed/refractory high-risk CLL with data expected 2021+ - ACE CL-311 for previously-untreated CLL (with venetoclax) with data expected 2021+ - Approximately 28,000 total patients in the US and EU treated or eligible (17,000 front-line; 11,000 relapsed/refractory). (Page 22) - Positive Phase III data readouts in CLL create momentum for future growth.

The provided pages do not include explicit future growth expectations specifically for earnings, operating earnings, profits, or EPS of AstraZeneca. However, some related insights are: - Forward-looking statements highlight risks and uncertainties affecting financial performance, including patent expirations, R&D outcomes, competition, regulatory approvals, and global economic conditions (Page 2). - The document notes momentum from Phase III data readouts in CLL, with ongoing trials and regulatory submissions supporting future growth potential (Page 22). - Calquence sales since launch reached $173m globally, with expansion expected due to additional pivotal trials and approvals (Page 22). - No direct quantified forecasts for earnings or EPS are provided. - AstraZeneca disclaims this presentation/webcast as a profit forecast (Page 2). For precise future earnings or EPS growth projections, please refer to dedicated financial reports or investor guidance from AstraZeneca.

The provided pages from the document "310.pdf" do not contain any information regarding the current or expected order book or pending orders for AstraZeneca. The content mainly focuses on: - Details about the Calquence Phase III ELEVATE TN trial for chronic lymphocytic leukemia (CLL), including efficacy, safety, patient demographics, and trial design. - AstraZeneca’s use of their conference materials. - Presentations and abstracts related to hematology and oncology areas at scientific meetings. - Forward-looking statements about business risks and factors. No financial data or order book information is presented in the provided pages.

The provided document (310.pdf) does not contain any information regarding current or future fundraising efforts by AstraZeneca through debt or equity. The content mainly focuses on: - Clinical trial data and updates for Calquence in CLL (chronic lymphocytic leukemia) - Safety and efficacy results from the Phase III ELEVATE TN trial - Presentation and conference call use restrictions - Forward-looking statements caution - Company sales figures and trial status updates No sections mention plans or activities related to raising capital via debt or equity issuance.